Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AR 6121

Drug Profile

AR 6121

Alternative Names: AR-6121

Latest Information Update: 16 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Aerie Pharmaceuticals
  • Developer Alcon
  • Class Anti-inflammatories; Drug conjugates; Eye disorder therapies; Steroids
  • Mechanism of Action Rho-associated kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Postoperative inflammation

Most Recent Events

  • 21 Jun 2021 Preclinical trials in Postoperative inflammation in USA (Ophthalmic), prior to June 2021 (Aerie Pharmaceuticals website, June 2021)
  • 21 Jun 2021 Aerie Pharmaceuticals announces intention to file an IND to the regulatory body for AR 6121 for Postoperative inflammation, in the second half of 2022 (Aerie Pharmaceuticals website, June 2021)
  • 21 Jun 2021 Aerie Pharmaceuticals expects regulatory approval of AR 6121 for Postoperative inflammation
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top